Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21

Gut

Volumn 55, Issue 12, 2006, Pages 1774-1780

  Monteleone, G ^a   Caruso, R ^a   Fina, D ^a   Peluso, I ^a   Gioia, V ^a   Stolfi, C ^a   Fantini, M C ^a   Caprioli, F ^a   Tersigni, R ^b   Alessandroni, L ^b   MacDonald, T T ^c   Pallone, F ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; GELATINASE A; GELATINASE B; HYBRID PROTEIN; INTERLEUKIN 21 RECEPTOR; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE INHIBITOR; MESALAZINE; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; ENZYME INDUCTION; ENZYME RELEASE; ENZYME SYNTHESIS; FIBROBLAST; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LAMINA PROPRIA; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

CELLS, CULTURED; COLITIS, ULCERATIVE; CROHN DISEASE; FIBROBLASTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKINS; INTESTINAL MUCOSA; MATRIX METALLOPROTEINASES; RECEPTORS, INTERLEUKIN-21; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845447347     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.093187     Document Type: Article

References (36)

1. Nagase H, Woessner JFJ. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
2. Murphy G, Reynolds JJ. Extracellular matrix degradation. In: Royce PM, Steinmann B, eds. Connective tissue and its heritable disorders: molecular, genetic, and medical aspects. New York: Wiley-Liss, 1993:287-316.
3. Louis E, Ribbens C, Godon A, et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol 2000;120:241-6.
4. von Lampe B, Barthel B, Coupland SE, et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000;47:63-73.
5. Pender SL, MacDonald TT. Matrix metalloproteinases and the gut - new roles for old enzymes. Curr Opin Pharmacol 2004;4:546-50.
6. Heuschkel RB, MacDonald TT, Monteleone G, et al. Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut 2000;47:57-62.
7. Salmela MT, MacDonald TT, Black D, et al. Upregulation of matrix metalloproteinases in a model of T cell mediated tissue injury in the gut: analysis by gene array and in situ hybridisation. Gut 2002;51:540-7.
8. Monteleone G, MacDonald TT, Wathen NC, et al. Enhancing Lamina propria Th1 cell responses with interleukin 12 produces severe tissue injury. Gastroenterology 1999;117:1069-77.
9. Pender SL, Tickle SP, Docherty AJ, et al. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 1997;158:1582-90.
10. Pender SL, Fel JM, Chamow SM, et al. A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol 1998;160:4098-103.
11. Kirkegaard T, Hansen A, Bruun E, et al. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut 2004;53:701-9.
12. Habib T, Nelson A, Kaushansky K. IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses. J Allergy Clin Immunol 2003;112:1033-45.
13. Collins M, Whitters MJ, Young DA. IL-21 and IL-21 receptor: a new cytokine pathway modulates innate and adaptive immunity. Immunol Res 2003;28:131-40.
14. Parrish-Novak J, Foster DC, Dolly HR, et al. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol 2002;72:856-63.
15. Habib T, Senadheera S, Weinberg K, et al. The common gamma chain (gamma c) is a required signaling component of the IL-21 receptor and support: IL-21-induced cell proliferation via JAK3. Biochemistry 2002;41:8725-31.
16. Jungel A, Distler JH, Kurowska-Stolarska M, et al. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 2004;50:1468-76.
17. Monteleone G, Monteleone I, Fina D, et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 2005;128:687-94.
18. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521-33.
19. Strong SA, Pizarro TT, Klein JS, et al. Proinflammatory cytokines differentially modulate their own expression in human intestinal mucosal mesenchymal cells. Gastroenterology 1998;114:1244-56.
20. Monteleone G, Biancone L, Marasco R, et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997;112:1169-78.
21. Brenne AT, Ro TB, Waage A, et al. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 2002;99:3756-62.
22. Ozawa A, Tada H, Tamai R, et al. Expression of IL-2 receptor beta and gamma chains by human gingival fibroblasts and up-regulation of adhesion to neutrophils in response to IL-2. J Leukoc Biol 2003;74:352-9.
23. Monteleone G, MacDonald TT. Manipulation of cytokines in the management of patients with inflammatory bowel disease. Ann Med 2000;32:552-60.
24. Swallow CJ, Murray MP, Guillem JG. Metastatic colorectal cancer cells induce matrix metalloproteinase release by human monocytes. Clin Exp Metastasis 1996;14:3-11.
25. Phillips PG, Birnby LM. Nitric oxide modulates caveolin-1 and matrix metalloproteinase-9 expression and distribution at the endothelial cell/tumor cell interface. Am J Physiol Lung Cell Mol Physiol 2004;286:L1055-65.
26. Lopez-Rivera E, Lizarbe TR, Martinez-Moreno M, et al. Matrix metalloproteinase 13 mediates nitric oxide activation of endothelial cell migration. Proc Natl Acad Sci USA 2005;102:3685-90.
27. Nguyen M, Arkell J, Jackson C. Active and tissue inhibitor of matrix metalloproteinase-free gelatinase B accumulates within human microvascular endothelial vesicles. J Biol Chem 1998;273:5400-4.
28. Taraboletti G, Sonzogni L, Vergani V, et al. Posttranscriptional stimulation of endothelial cell matrix metalloproteinases 2 and 1 by endothelioma cells. Exp Cell Res 2000;258:384-94.
29. Leveque T, Le Pavec G, Boutet A, et al. Differential regulation of gelatinase A and B and TIMP-1 and -2 by TNFalpha and HIV virions in astrocytes. Microbes Infect 2004;6:157-63.
30. Limb GA, Daniels JT, Pleass R, et al. Differential expression of matrix metalloproteinases 2 and 9 by glial Muller cells: response to soluble and extracellular matrix-bound tumor necrosis factor-alpha. Am J Pathol 2002;160:1847-55.
31. Di Girolamo N, Lloyd A, McCluskey P, et al. Increased expression of matrix metalloproteinases in vivo in scleritis tissue and in vitro in cultured human scleral fibroblasts. Am J Pathol 1997;150:653-66.
32. Di Girolamo N, Verma MJ, McCluskey PJ, et al. Increased matrix metalloproteinases in the aqueous humor of patients and experimental animals with uveitis. Curr Eye Res 1996;15:1060-8.
33. Fujina S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003;52:65-70.
34. Andoh A, Zhang Z, Inatomi O, et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 2005;129:969-84.
35. Wang G, Tschoi M, Spolski R, et al. In vivo antitumor activity of interleukin-21 mediated by natural killer cells. Cancer Res 2003;63:9016-22.
36. Pelletier M, Bouchard A, Girard D. In vivo and in vitro roles of IL-21 in inflammation. J Immunol 2004;173:7521-30.